# Verbund

Type: Company (OEZVY)

Source: GetYourBrief — https://getyourbrief.com/entity/verbund
Canonical HTML page: https://getyourbrief.com/entity/verbund

## Timeline

- **2026-Q4**: Data Readout — Anticipated top-line data from the Phase 3 VERIFY clinical trial.
- **2026-03-18**: Q4 Earnings — Scheduled announcement of quarterly financial results and pipeline update.
- **2026-03-18**: Quarterly Earnings — Expected announcement of financial results and pipeline updates for PTGX and OEZVY.
- **2026-03-18**: Quarterly Earnings Release — Official financial results and conference calls scheduled for both companies.
- **2026-03-17**: Pre-Earnings Market Activity — Both OEZVY and PTGX see increased trading volume ahead of Wednesday reports.
- **2026-02-26**: Takeda Deal Restructuring — Protagonist opts out of profit-sharing for Rusfertide in exchange for $400M cash.
- **2025-Q4**: JNJ-2113 Phase 3 Progress — Johnson & Johnson advances oral peptide JNJ-2113 into pivotal trials.
- **2025-01-10**: VERIFY Enrollment — Completion of enrollment for the Phase 3 trial of rusfertide in polycythemia vera.
- **2024-05-15**: J&J Milestone — Protagonist receives $231M milestone payment for icotrokinra progress.
- **2024-01-31**: Takeda Partnership — Protagonist signs a global licensing agreement for rusfertide with $300M upfront.

## Recent coverage (3 stories, network-wide)

### Verbund and Protagonist Therapeutics Set for Key Mid-Week Earnings Reports
2026-03-17 07:34:46 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Austrian utility giant Verbund and biotech firm Protagonist Therapeutics are scheduled to release quarterly results this Wednesday. Investors will be scrutinizing Verbund's hydropower margins and Protagonist's cash position following its recent $400 million deal with Takeda.
Full story: https://getfinancebrief.com/story/verbund-protagonist-earnings-preview-march-2026

### Protagonist Therapeutics Braces for Q1 Earnings Amid Pipeline Milestones
2026-03-17 07:33:39 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Protagonist Therapeutics (PTGX) is set to report quarterly earnings this Wednesday, with investors focused on the commercial trajectory of its Takeda-partnered rusfertide. The results come at a critical juncture as the company transitions from a clinical-stage R&D house to a commercially-oriented biotech entity.
Full story: https://getbiobrief.com/story/protagonist-therapeutics-verbund-earnings-preview-2026

### Protagonist Therapeutics Eyes Pivotal Q4 Results Amid Oral Peptide Expansion
2026-03-17 07:33:05 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Protagonist Therapeutics (PTGX) is scheduled to release its quarterly earnings on Wednesday, March 18, 2026, with investors focused on the commercialization path for rusfertide and the Phase 3 progress of its oral IL-23 receptor antagonist, icotrokinra. The results will provide a critical update on the company's transition from a clinical-stage biotech to a potential commercial powerhouse in the immunology and hematology sectors.
Full story: https://gethealthbrief.com/story/protagonist-therapeutics-q4-earnings-preview-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.